Trial Profile
Dose-escalation study of apitolisib (GDC-0980) in patients with advanced malignant pleural mesothelioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Apitolisib (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 15 Dec 2015 New trial record